The Complications of Controlling Agency Time Discretion: FDA Review Deadlines and Postmarket Drug Safety

  1. Daniel Carpenter1,
  2. Jacqueline Chattopadhyay2,
  3. Susan Moffitt3,
  4. Clayton Nall4

Article first published online: 14 OCT 2011

DOI: 10.1111/j.1540-5907.2011.00544.x

Issue

American Journal of Political Science

American Journal of Political Science

Volume 56, Issue 1, pages 98–114, January 2012

Additional Information

How to Cite

Carpenter, D., Chattopadhyay, J., Moffitt, S. and Nall, C. (2012), The Complications of Controlling Agency Time Discretion: FDA Review Deadlines and Postmarket Drug Safety. American Journal of Political Science, 56: 98–114. doi: 10.1111/j.1540-5907.2011.00544.x

Author Information

  1. 1

    Harvard University

  2. 2

    Harvard University

  3. 3

    Brown University

  4. 4

    Stanford University

*Daniel Carpenter is Allie S. Freed Professor of Government, Harvard University, 1737 Cambridge Street, Cambridge, MA 02138, and (2011–2012) Visiting Researcher, Institut d’Études Politiques, Université de Strasbourg, France (dcarpenter@gov.harvard.edu). Jacqueline Chattopadhyay is a Ph.D. candidate in Government & Social Policy, Harvard University, 1737 Cambridge Street, Cambridge, MA 02138 (jchattop@fas.harvard.edu). Susan Moffitt is Mary Tefft and John Hazen White Sr. Assistant Professor of Political Science, Brown University, 36 Prospect Street, Providence, RI 02912 (Susan_Moffitt@brown.edu). Clayton Nall is Assistant Professor of Political Science, Stanford University, 616 Serra Street, Encina Hall West, Room 100, Stanford, CA 94305–6044 (nall@stanford.edu).

  1. For critical remarks and helpful discussions, we thank Jerry Avorn, Einer Elhauge, Gary King, Bruce Psaty, Meredith Rosenthal, Katherine Swartz, Heidi Williams, the Editor and anonymous reviewers, and audiences at Harvard Medical School, Harvard Law School, the Keck Graduate Institute of Applied Life Sciences, and the Ohio State University. Carpenter acknowledges the National Science Foundation (SES-0076452 and SES-0351048), a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, and the Safra Center for Ethics at Harvard University. Carpenter and Moffitt also acknowledge the Robert Wood Johnson Foundation Scholars in Health Policy Research Program. All replication data and code for this article will be available on the date of publication at http://people.hmdc.harvard.edu/~dcarpent/fdaproject/deadlinesstudy2011.html.

Publication History

  1. Issue published online: 17 JAN 2012
  2. Article first published online: 14 OCT 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (613K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Get PDF (613K)